32 results about "Postmenopausal osteoporosis" patented technology

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The invention relates to the field of disease animal model construction, and particularly discloses a postmenopausal osteoporosis and knee osteoarthritis co-disease animal model construction method which comprises the following steps: selecting a female animal as an experimental subject; the selected female animals are injected with a GnRH agonist, meanwhile, low-calcium feed feeding and oxidative stress stimulation are conducted, and feeding is conducted for a preset time; detecting bone mineral density and bone trabecula parameters of the fed female animals, and screening qualified female animals meeting set standards; performing meniscus tearing operation on the qualified female animal, and implanting sustained release microspheres loaded with inflammatory factors at the torn part during the operation; carrying out weight-bearing training on the female animal after the operation, and continuing for a set time length; and performing health detection on the female animals at different time points. According to the method, through multi-factor collaborative induction of the PMOP, minimally invasive construction of the KOA and multi-dimensional health detection, accurate simulation of a co-disease pathological process and clinical characteristics is realized, and the authenticity and stability of the model are improved.

The invention provides an application of miR-337 in preparation of a medicine for treating osteoporosis, which is used for the medicine for treating osteoporosis, and relates to the technical field of biomedicine. The research of the inventor finds that miR-337 can activate p53 to promote apoptosis of osteoclasts, has a certain treatment effect on osteoporosis, and can be used for preparing the medicine for treating osteoporosis; the nano vesicles derived from human umbilical cord mesenchymal stem cells have certain anti-inflammatory activity and have a positive effect on treatment of osteoporosis. According to the application disclosed by the invention, miR-337 is further loaded on nano vesicles derived from human umbilical cord mesenchymal stem cells, and the research of the inventor finds that the medicine has a good treatment effect on osteoporosis, provides a new strategy for preventing postmenopausal osteoporosis, and has remarkable clinical transformation potential.

The invention discloses a telmisartan glucoside derivative, a microbial conversion preparation method thereof and application of the telmisartan glucoside derivative in preparation of a medicine for preventing or treating osteoporosis. The telmisartan glucoside derivative is characterized in that a telmisartan propyl side chain is connected with a glucosyl group. According to the invention, a microbial conversion technology is utilized, telmisartan is taken as a substrate, and glucosyl is introduced into a telmisartan propyl side chain in a regioselective manner, so that the telmisartan glucoside derivative with a novel structure is obtained. Experiments on the osteoblast proliferation promoting activity and the postmenopausal osteoporosis resisting effect of the telmisartan glucoside derivative by using an in-vitro osteoblast model and an ovariectomized induced osteoporosis mouse model prove that the telmisartan glucoside derivative has relatively good osteoblast proliferation promoting activity and postmenopausal osteoporosis resisting activity; the compound can be used as an active component of a medicine for treating osteoporosis, and has wide application.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

The invention discloses application of a let-7e inhibitor loaded on nano-vesicles derived from bone marrow mesenchymal stem cells in preventive treatment of postmenopausal osteoporosis, and belongs to the technical field of biological medicines. According to the invention, the let-7e inhibitor is designed and synthesized and is'neutralized ', so that the inhibition of the let-7e inhibitor on an osteogenic gene is relieved, the osteogenic function of osteoblasts is promoted, and meanwhile, the nano-vesicles which are derived from mesenchymal cells and have an anti-inflammatory effect are selected as a delivery tool of the let-7e inhibitor to prevent and treat osteoporosis. Experimental results indicate that the mouse bone marrow mesenchymal stem cell-derived nano-vesicle loaded with the let-7e inhibitor has a good preventive treatment effect on mouse osteoporosis after ovariectomy. A stem cell nano-vesicle treatment platform based on mouse bone marrow mesenchymal stem cell-derived nano-vesicles loaded with let-7e inhibitors is expected to be developed into a novel clinical intervention scheme for preventing postmenopausal osteoporosis.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

The invention discloses a compound traditional Chinese medicine preparation for treating postmenopausal osteoporosis, osteoarthritis and / or premature ovarian insufficiency as well as a preparation method and application of the compound traditional Chinese medicine preparation, and belongs to the technical field of traditional Chinese medicines. The compound traditional Chinese medicine preparation is prepared from the following components: 10 to 30 g of radix rehmanniae preparata, 10 to 30 g of radix angelicae sinensis, 8 to 15 g of rhizoma chuanxiong, 8 to 15 g of radix paeoniae alba, 10 to 30 g of radix codonopsis, 8 to 15 g of rhizoma atractylodis macrocephalae, 10 to 30 g of poria cocos, 5 to 10 g of liquorice root, 10 to 30 g of radix dipsaci, 8 to 15 g of radix achyranthis bidentatae, 8 to 15 g of fructus chaenomelis lagenariae, the compound traditional Chinese medicine preparation provided by the invention realizes effective treatment on osteoporosis, osteoarthritis and early-onset ovarian insufficiency, overcomes various defects of an existing treatment method, remarkably improves the treatment effect, reduces the side effects of medicines, and brings a new treatment choice for patients. And a new thought and a new method are expected to be provided for solving the treatment problem of the three diseases.

This invention discloses the application of an inhibitor of transcription factor C / EBPβ in the preparation of a drug for treating postmenopausal osteoporosis. This invention also discloses the application of transcription factor C / EBPβ in screening drugs that reduce postmenopausal FSH levels, wherein the drugs inhibit the expression of transcription factor C / EBPβ. Furthermore, this invention discloses the application of compounds #11a and CF3CN in the preparation of a drug for treating postmenopausal osteoporosis. This invention reveals for the first time that the C / EBPβ-AEP pathway participates in promoting FSHβ synthesis in a menopausal model. By reducing the transcription factor activity of C / EBPβ, it can reduce FSH expression at the pituitary gland, promote osteogenic differentiation, inhibit osteoclast resorption, and effectively alleviate PMOP symptoms. Compounds #11a and CF3CN can effectively achieve both anti-bone resorption and bone formation-promoting functions, achieving coupled treatment of PMOP.

The invention relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of the bone mineral density through the deviation change of the bone mineral density risk value in time sequence, and combines the initial bone mineral density risk to divide the group and analyze and identify the risk degree of the group; coupling the drop fluctuation characteristics of hormones with the change of bone metabolism markers to obtain the comprehensive metabolic risk influence degree; determining the comprehensive influence degree of osteoporosis by utilizing the group comprehensive bone mineral density risk degree dynamic adjustment and combining the external risk influence degree and the comprehensive metabolic risk influence degree; and based on the osteoporosis comprehensive influence degree of the sample data, training a neural network model to carry out risk prediction. According to the method, the risk model is constructed by considering the multi-dimensional influence of hormone metabolism and behavioral habits of the postmenopausal patient and the multi-dimensional coupling evaluation value, so that the risk prediction accuracy is improved, and more comprehensive and reliable data support is provided for bone health management of postmenopausal women.

This invention provides the application of Neoruscogenin in the preparation of anti-osteoporosis drugs, belonging to the field of pharmaceutical biotechnology. It was found that Neoruscogenin can significantly increase bone volume fraction, bone surface area to tissue volume ratio, bone mineral density, trabecular bone number, and trabecular bone thickness in osteoporotic mice, while significantly reducing trabecular bone separation; that is, Neoruscogenin can alleviate low bone mass in postmenopausal osteoporotic mice. Furthermore, Neoruscogenin treatment for 8 weeks did not significantly affect the major organs of mice, suggesting the biocompatibility of Neoruscogenin.

The invention discloses a bone-targeted functionalized tetrahedral framework nucleic acid nano system as well as a preparation method and application thereof, the bone-targeted functionalized tetrahedral framework nucleic acid nano system comprises tetrahedral framework nucleic acid tFNA-Sa, polypeptide SDSSD with bone cell specific targeting and an osteoporosis treatment drug, the bone targeting tetrahedral framework nucleic acid tFNA-Sa is used for modifying bone targeting polypeptide to obtain the bone targeting tetrahedral framework nucleic acid tFNAs-SDSSD, the editability and the biocompatibility of the nucleic acid tetrahedron are utilized, the SDSSD bone targeting peptide is modified on the surface of the tetrahedron, the bone targeting ability can be given to the bone targeting peptide, and then the purposes of efficient aggregation of the medicine in bone tissue, high-efficiency drug delivery and the like are achieved. The distribution of the medicine in non-target tissues is reduced. The targeted delivery system not only can improve the treatment effect of the medicine, but also can greatly reduce the side effect of the medicine, and brings a new scheme for targeted therapy for postmenopausal osteoporosis.

The present application relates to the application of Radix Rehmanniae Preparata polysaccharide in postmenopausal osteoporosis, and relates to the application of active ingredients of traditional Chinese medicine in the treatment of bone metabolism diseases. The Radix Rehmanniae Preparata polysaccharide can improve the postmenopausal osteoporosis by up-regulating the expression of estrogen receptors and promoting the synthesis of estrogen.

This invention provides an application of the PDK4 gene, which is used to prepare drugs to improve postmenopausal osteoporosis. PDK4 gene deletion in bone marrow mesenchymal stem cells (BMSCs) reduces their osteogenic differentiation capacity and inhibits mitochondrial division by blocking the E2-DRP1 signaling axis. Overexpression in bone tissue reverses bone formation inhibition caused by postmenopausal osteoporosis. This invention redefines the biological function of the PDK4 gene in the skeletal system. This gene promotes osteogenic differentiation of BMSCs through the E2-ERα-PDK4-MYH9-DRP1 signaling axis, thus improving postmenopausal osteoporosis and providing a new theoretical framework and potential target for developing bone-promoting therapies for postmenopausal osteoporosis.

The invention discloses a preparation method and application of soybean-sourced nano phytoestrogen nano vesicles, belongs to the technical field of biological nano materials, solves the technical problems of poor bone targeting ability and low bioavailability of supplemented exogenous estrogens, and comprises the following steps: S1, weighing, cleaning and soaking; s2, crushing and filtering; s3, performing differential centrifugation; s4, performing extrusion to obtain nano phytoestrogen nano vesicles (SVs) from soybeans, and storing the nano phytoestrogen nano vesicles (SVs) at-80 DEG C for later use; the prepared SVs are applied to preparation of medicines for treating postmenopausal osteoporosis diseases. The soybean-sourced phytoestrogen nano-vesicle prepared by combining a differential centrifugation method with an extrusion method is wide in raw material source and simple in extraction process, is used as a plant estrogen, is rich in various bioactive components such as proteins, lipids and isoflavonoids, reverses the state of bone resorption and bone formation imbalance under the estrogen deficiency state, and has a good application prospect. And a new solution is provided for the treatment of postmenopausal osteoporosis.

The invention discloses the application of the Chinese wolfberry fruit-glossy privet fruit and calcitriol composition in the medicine for treating postmenopausal osteoporosis for the first time, and through three-layer research of'in vitro cell-animal model-molecular pathway ', it is clear that the composition can bidirectionally regulate and control kidney vitamin D metabolic enzyme by activating'PI3K-AKT' signal pathway for the first time, so that the curative effect on postmenopausal osteoporosis is achieved. Further, the serum 25 hydroxyl vitamin D and blood calcium level are improved, and the bone mineral density is improved. The mechanism provides a modern molecular biology support for the traditional Chinese medicine theory of'kidney dominating bone ', and also establishes a new path of'regulating kidney metabolic enzyme to treat osteoporosis'. By optimizing the metabolic bone protection effect of the vitamin D, bone loss of ovariectomized mice is effectively delayed, meanwhile, the vitamin D and calcitriol play a synergistic effect, and the vitamin D has a multi-target bone protection effect in postmenopausal PMOP, has anti-osteoporosis activity and can be used for treating the PMOP.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a kidney-tonifying and liver-nourishing compound preparation in preparation of a medicine for improving postmenopausal osteoporosis, and the kidney-tonifying and liver-nourishing compound preparation comprises the following components in parts by weight: 5-15 parts of roasted herba epimedii, 5-15 parts of fructus cnidii, 50-70 parts of roasted astragalus membranaceus and 10-30 parts of dogwood. Experiments show that the kidney-tonifying and liver-nourishing compound preparation can improve the problems of gap enlargement and structure looseness of bone tissue morphology and can inhibit bone loss, namely, the kidney-tonifying and liver-nourishing compound preparation has the effect of improving postmenopausal osteoporosis; compared with a traditional estrogen replacement therapy, the kidney-tonifying and liver-nourishing compound preparation has the advantages that the side effects are obviously reduced, the safety is improved, and a foundation is laid for developing safe and effective anti-osteoporosis medicines in the future.

The application discloses application of a medicine, miltefosine, in promoting bone formation and preventing and treating osteoporosis. In the bone formation process, the expression of protein phosphatase PPM1A in osteoblasts is significantly increased, the dephosphorylation of a core protein Smad2 of a TGF-beta signal path is regulated, the TGF-beta signal path is inhibited, the expression of an osteogenic marker is promoted, and the osteogenic ability of the organism is enhanced. The application discloses that the medicine, miltefosine, is used as a PPM1A enzyme activity catalyst, the in-vivo intervention of the medicine can significantly accelerate bone repair and delay bone loss of postmenopausal osteoporosis, a mechanism is that the enzyme activity of PPM1A of osteoblasts is catalyzed, the dephosphorylation of Smad2 protein is promoted, the TGF-beta / Smad2 signal path activity is inhibited, bone formation is promoted, bone repair is accelerated, and bone loss is prevented. Therefore, the miltefosine has a good application prospect in clinical treatment of promoting osteogenesis and preventing and treating osteoporosis.

This invention discloses the use of CPT2 inhibitors in the treatment of postmenopausal osteoporosis. By detecting fatty acid oxidation levels in osteoclast precursor cells and CPT2 expression levels, postmenopausal osteoporosis can be predicted. It also discloses the use of CPT2 as a diagnostic marker for postmenopausal osteoporosis. The CPT2 inhibitors include perhexiline maleate, among others. This invention reveals a new use of CPT2 as a marker and therapeutic target for postmenopausal osteoporosis, providing important evidence for the clinical application of CPT2 inhibitors.

The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition for treating osteoporosis, a preparation and a preparation method and application thereof. The medicine composition is prepared from the following medicinal materials in parts by weight: 5 to 10 parts of herba epimedii, 10 to 15 parts of tortoise plastron, 6 to 12 parts of rhizoma anemarrhenae, 10 to 15 parts of radix rehmanniae recen, 10 to 15 parts of radix astragali, 6 to 12 parts of herba dendrobii, 6 to 12 parts of radix curcumae, 6 to 12 parts of rhizoma cyperi, 10 to 15 parts of semen cuscutae, 3 to 8 parts of colla corii asini, 10 to 15 parts of caulis spatholobi, 6 to 12 parts of cortex phellodendri, 10 to 15 parts of rhizoma drynariae and 10 to 15 parts of radix dipsaci. According to the present invention, the pathogenesis of the postmenopausal osteoporosis is deeply analyzed, the corresponding treatment method and the corresponding treatment rule are formulated according to the pathogenesis, the unique compatibility relationship between the compositions is finally formed, and the new osteoporosis treatment pharmaceutical composition is provided, is the pure traditional Chinese medicine preparation, has characteristics of no significant toxic-side effect, no side effect, no toxic-side effect, and no side effect, and can be used for treating the postmenopausal osteoporosis. Animal experiments prove that the traditional Chinese medicine preparation has a remarkable curative effect on postmenopausal osteoporosis.

The invention belongs to the technical field of medicine research and development, and provides application of edaravone in preparation of a medicine for treating postmenopausal osteoporosis aiming at the technical problem that whether edaravone has a treatment effect on postmenopausal osteoporosis or not is not reported at present. In addition, by constructing a mouse ovariectomized model and combining with a ferroptosis-induced osteogenesis / osteoclast system, the edaravone is proved to be capable of effectively increasing calcium salt deposition and mineralization after osteoporosis, improving poor osteogenesis of osteoblasts and osteoblast inflammatory response caused by osteoporosis, effectively improving FSP1 expression and improving osteoporosis. And meanwhile, the expression of 5-LOX and ACSL4 proteins is reduced, and the intraosseous ferroptosis microenvironment of the postmenopausal osteoporosis is regulated through ways of inhibiting ROS, inhibiting lipid peroxidation and the like, so that the treatment effect of relieving the progress of the postmenopausal osteoporosis is achieved.

The present application relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of bone mineral density by the deviation change of bone mineral density risk value in time sequence, combines with the initial detection of bone mineral density risk to divide groups and analyze and identify the group risk degree; the comprehensive metabolic risk influence degree is obtained by coupling the hormone drop fluctuation characteristics with the bone metabolism marker change; the osteoporosis comprehensive influence degree is determined by using the group comprehensive bone mineral density risk degree dynamic adjustment, combining with the external risk influence degree and the comprehensive metabolic risk influence degree; and the neural network model is trained based on the osteoporosis comprehensive influence degree of sample data to predict the risk. The present application considers the multidimensional influence of postmenopausal patient's internal hormone metabolism and behavior habit, constructs the risk model by multidimensional coupling evaluation value, improves the risk prediction accuracy, and provides more comprehensive and reliable data support for the bone health management of postmenopausal women.

The invention provides application of a lignum dalbergiae odoriferae extract in a medicine for improving postmenopausal osteoporosis, and relates to the field of biological medicines. Experiments show that the lignum dalbergiae odoriferae extract can improve the problems of gap enlargement and structure looseness of bone tissue morphology, can inhibit bone loss, and can improve BGP and ALP levels, that is, the lignum dalbergiae odoriferae extract has the effect of improving postmenopausal osteoporosis; and compared with the traditional estrogen replacement therapy, the side effects of the dalbergia wood extract in the application are obviously reduced, and the safety is improved.

The application discloses application of hsa-miR-144-5p as a postmenopausal osteoporosis diagnosis marker. The application adopts high-throughput gene chip technology to detect serum miRNA expression profiles of PMOP patients, and compares with postmenopausal non-osteoporosis population, screens differential expression miRNAs between the two, further verifies the differential level of the selected miRNA between the PMOP patients and n-PMOP through real-time fluorescent quantitative PCR technology, confirms the clinical application value of the screened marker, and finally provides a simple and easy, high-precision biomarker for clinical PMOP diagnosis.

The present application relates to a kind of protein markers for diagnosing postmenopausal osteoporosis and its application, belong to biological medicine technical field.The present application is screened, and it is found that NADH dehydrogenase 1 beta subcomplex subunit 4, NADH dehydrogenase 1 beta subcomplex subunit 5, NADH dehydrogenase 1 beta subcomplex subunit 6, NADH dehydrogenase 1, NADH dehydrogenase 1 alpha subcomplex subunit 8, cytochrome c oxidase subunit 7C, cytochrome c oxidase subunit 5A and cytochrome c oxidase subunit 7A2 can be used alone or in combination in the diagnosis test of postmenopausal osteoporosis, to accurately evaluate the PMOP state of subject.Further, the combination of NDUB5 and NDUA8 two protein markers shows excellent diagnostic sensitivity and specificity, which is helpful for early diagnosis of PMOP, screening of high-risk population of fracture and precise prevention and treatment.

The invention relates to a protein marker for diagnosing postmenopausal osteoporosis and application thereof, and belongs to the technical field of biological medicine. Through screening, an NADH dehydrogenase 1 beta sub-complex subunit 4, an NADH dehydrogenase 1 beta sub-complex subunit 5, an NADH dehydrogenase 1 beta sub-complex subunit 6, an NADH dehydrogenase 1, an NADH dehydrogenase 1 alpha sub-complex subunit 8, a cytochrome c oxidase subunit 7C, a cytochrome c oxidase subunit 5A and a cytochrome c oxidase subunit 7A2 are found. The kit can be used in a diagnostic test of postmenopausal osteoporosis independently or in a combined manner, so as to accurately evaluate the PMOP state of a subject. Furthermore, the combination of the two protein markers NDUB5 and NDUA8 shows excellent diagnosis sensitivity and specificity, and is beneficial to early diagnosis of PMOP and screening and precise prevention and treatment of high-risk groups of fracture.

The present application relates to the application of 5-amino pentanamide in the preparation of osteoporosis diagnostic products, belonging to the field of biotechnology. Non-targeted metabolomics analysis is carried out on the plasma exosomes of 100 postmenopausal osteoporosis patients (case group) and 100 healthy controls (control group), and further variable screening of differential metabolites is carried out by LASSO regression, and it is found that the regression coefficient absolute value of 5-amino pentanamide (5-Aminopentanamide) is the largest, which is the most critical metabolite for distinguishing the case group from the control group. The content of 5-amino pentanamide in the case group is significantly lower than that in the control group, and the area under the curve (AUC) is 0.903, which has good prediction effect. The diagnostic marker of the present application significantly improves the accuracy and specificity of postmenopausal osteoporosis diagnosis.

The invention discloses engineered clostridium sporogenes with high yield of indole-3-propionic acid as well as a preparation method and application of the engineered clostridium sporogenes, and belongs to the technical field of bioengineering. The engineered clostridium sporogenes is an engineered clostridium sporogenes carrying a recombinant plasmid pMTL82151-fldAIBC, and the recombinant plasmid pMTL82151-fldAIBC is a recombinant plasmid pMTL82151 The content of IPA in a bone microenvironment is increased by stably and highly expressing IPA, the bone metabolism dual regulation and control functions of promoting osteogenesis and inhibiting osteoclast are exerted, the homeostasis of bone formation and bone resorption is recovered, and postmenopausal osteoporosis is improved; the composite has the functions of doubly adjusting bone metabolism and improving bone mass, has common advantages of probiotic therapy, has good biological safety, can be produced in an expanded mode through culture in the later period, is convenient to prepare and has wide application prospects.

The application discloses application of a lignan and flaxseed polysaccharide in preparation of health care products for improving osteoporosis, and belongs to the technical field of health care functions. The postmenopausal osteoporosis model is established by ovariectomized rats, and the comparison of the lignan and flaxseed polysaccharide on bone metabolism, related bone conversion indexes, bone microstructure, bone biomechanics and intestinal flora of the rats is systematically studied, so that the dominant material for improving osteoporosis of the lignan and flaxseed polysaccharide is explored, and a more effective theoretical basis is provided for development of functional food of flaxseed.

This invention discloses the use of donkey-hide gelatin in the preparation of products for treating postmenopausal osteoporosis, belonging to the field of new pharmaceutical applications of donkey-hide gelatin. The use of donkey-hide gelatin in the preparation of products for treating postmenopausal osteoporosis utilizes a mechanism of action that regulates immune cells to mediate bone immune balance, thus treating osteoporosis. This invention reveals for the first time a novel mechanism by which donkey-hide gelatin regulates immune cells to mediate bone immune balance. This mechanism endows traditional donkey-hide gelatin with entirely new pharmaceutical value, exceeding expectations based on its traditional description as "strengthening muscles and bones." It indicates that donkey-hide gelatin can be used to prepare drugs or health products for treating postmenopausal osteoporosis, and is particularly suitable for the development of anti-osteoporosis preparations based on immune modulation mechanisms.